We describe a novel double-labeling method to simultaneously inwstigate proliferation and apoptmis ftom plastic-embedded biopsy specimens (PEBs). Infusions of bromo-andlor iododeoxyuridine (BrdUIIudR) were given to 10 patients, five with acute myeloid leukemia (AML) and five with myelodysplastic syndromes (MDS), and S-phase cells were measured in PE& using a monoclonal anti-IudRIBrdU antibody. Apoptosis was measured by in situ end-labeling (ISEL) of DNA. The results demonstrate that both AML and MDS are highly proliferative disorders but that there is almost no apoptosis in the former, whereas extensive apoptosis was observed in the latter. Double labeling revealed that large numbers of S-phase cells in MDS were simultaneously undergo-
Introduction
There are several compelling reasons why studies designed to measure such critical biological properties as cell birth and cell death rates of human malignancies should ideally be conducted on architecturally preserved biopsy tissues. The two most obvious advantages are that individual cells, rather than the population as a whole, can be examined and morphological recognition allows selective exclusion of non-malignant cells such as normal stromal elements or tumor-infiltrating lymphocytes. This is why our protocols designed to examine the proliferation rates of a variety of human tumors provide for in vivo labeling of S-phase cells using the thymidine analogues iodo-and bromodeoxyuridine (IudRI BrdU), followed by immunohistochemical detection of these compounds in plastic-embedded biopsy specimens (PEBs) (1-3). For studies aimed at estimating the incidence of programmed cell death (PCD) or apoptosis, the ability to examine biopsy sections acquires even greater significance. For one thing, individual cells which are ing apoptosis. We conclude that the high cell death in MDS cancels the high cell birth, resulting in a functionally aplastic marrow and thus accounting for the observed inefhive hematopoiesis. On the other hand, A M L is rapidly fatal, probably owing to high cell birth with no or " a l cell death. Therapeutic strategies to prevent intramedullary programmed cell death of hematopoietic precursors should be evaluated in MDS, and efficacy of chemotherapy in AML can be assessed by measuring the induction of apoptosis in post-treatment biopsy specimens. (JHistochem Cytochem KEY WORDS: AML; MDS; Apoptosis; Proliferation; BrdU IudR; In situ end-labeling of DNA. :1533-1537, 1994) pre-karyorrhectic and in earlier stages of apoptosis can be recognized by in situ end-labeling (ISEL) of DNA (4). Second, by double labeling for IudR/BrdU and ISEL simultaneously, highly accurate estimations of cell birth and cell death rates can be obtained from the same tissue section, thereby providing the true doubling time of tumors.
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In the present study we examined the bone marrow biopsies of 10 patients, five of whom had a diagnosis of acute myeloid leukemia (AML) and five had myelodysplastic syndromes (MDS), for simultaneous assessment of proliferation and apoptosis. Each patient had received an IV infusion of IudR and/or BrdU, and anti-IudR/BrdU monoclonal antibodies (MAbs) were used to identlfy S-phase cells in the post-infusion bone marrow (BM) biopsies, which were embedded in plastic with glycol methacrylate. PCD was measured in individual cells using ISEL, a technique that not only identifies morphologically apparent karyorrhectic cells but also labels cell in which the DNA fragmentation has not yet progressed to frank nuclear fragmentation. This technique is based on the simple premise that during apoptotic cell death, double-stranded DNA fragments of 180-200 BP (or their multiples thereof) are created which have peculiar recessed 3' ends (5-7). By using biotinylated nucleotides and a DNA polymerase in situ, the overhanging 5' ends can be used as templates to synthesize new DNA strands, which are visible on light microscopy after histochemical development. The present report describes our novel in situ technique to simultaneously assess cell birth and cell death rates of hematopoietic cells in two disorders of the myeloid cells.
Materials and Methods
Ten patients with a confirmed diagnosis of myelodysplastic syndrome (five patients) and AML (five patients) are the subject of this report. Every patient received a l-hr IV infusion of bromodcoxyuridine at 100 mg/m2 per protocol DS 86-15 and/or iododeoxyuridine at 100 mg/m2 on protocol MDS 90-02. Informed consent was obtained from every patient before the infusion. The infusion protocols were approved by the local Institution Review Board (IRB), the National Cancer Institute (NCI) and the Food and Drug Administration (FDA). The drugs were supplied by the NCI. No patient had received any therapy except for supportive care for at least 2 weeks before receiving IudR and/or BrdU for cell cycle studies. As a control population for the studies of programmed cell death, bone marrow biopsy specimens from two patients with non-Hodgkin's lymphoma (NHL) were also studied. These patients also received IudR and/or BrdU. Detailed methodology is described below.
Assessment of Cell Proliferation with Intravenous Thymidine Analogues IudR and/or BrdU
The thymidine analogues IudR and/or BrdU were infused IV with a constant rate infusion pump. Immediately at the end of the last infusion, peripheral blood (PB), bone marrow aspirate (BM asp), and biopsy samples were obtained. The BM asp were double labeled in vitro with tritiated thymidine for calculation of duration of S-phase by our previously described method (3). The BM biopsies were fixed in Bouin's solution and processed in plastic with glycol methacrylate. Sections of 2-3 pm were obtained from these biopsies with a tungsten carbide-edged microtome and placed on Alcian Blue-coated coverslips. Air-dried sections were then processed by the monoclonal anti-BrdU/IudR antibody (Oncogene Science; Cambridge, MA) as previously described (3). After processing, the coverslips were counterstained with hematoxylin and May-Grunwald stains. At least 2000 positively labeled S-phase cells were counted from five or more areas of the biopsy for determination of the labeling-index (LI%).
Assessment of Programmed Cell Depth or Apoptosis with In Situ End-labeling Technique
Two-pm sections from the previously mentioned BM biopsies were obtained. The sections were rehydrated in distilled water for 10 min, then incubated with freshly diluted 3% H202 for 30 min. Specimens were thoroughly rinsed in 0.15 M PBS, pH 7.5; 0.15 M sodium chloride (NaCI) in 0.1 M phosphate buffer. They were then incubated with SSC (0.3 M NaCl and 30 mM Na-citrate, pH 7.0) at 80'C for 20 min, followed by thorough washing with 0.15 M PBS. The sections were next treated with pronase (1.0 mglml in 0.5 M PBS; Calbiochem, LaJolla, CA) at room temperature (RT) for 30 min. After this they were rinsed first in 0.15 M PBS and then in Buffer A, pH 7.5 (50 mM Trizma HCI, 5 mM magnesium chloride, 10 mM P-mercaptoethanol, and 0.005% BSA, fraction V; Sigma, St Louis, MO). Subsequently, the sections were incubated with ISEL solution prepared in Buffer A [0.01 mM dATP, dGTP, dCTP (Promega; Madison, WI), 0.001 mM biotin-11-dUTP (Sigma), and 20 Ulml E. coli DNA polymerase I (Promega)] at 18'C for 2 hr, followed by washing with Buffer A and later with 0.5 M PBS (0.5 M NaCl in 0.1 M phosphate buffer, pH 7.5). Then the specimens were incubated with avidin-biotin-horseradish peroxidase conjugate (Vectastain Elite ABC Kit; Vector, Burlingame, CA) diluted 1:25 in 0.5 M PBS containing 1% BSA and 0.5% Tween 20. Eventually samples were stained with 0.04% 3,3'-diaminobenzidine tetrahydrochloride (DAB) diluted in 0.05 M Xis buffer, pH 7.5, with 0.015% of 30% H202 for 10 min and rinsed well with distilled water. The specimens were then mounted with Fluoromount. Slides were left to dry overnight before estimation of PCD.
Simultaneous Assessment of Cell Birth (Proliferation) and Cell Death (Apoptosis) from the Same Biopsy Section with Double Labeling by ISEL and anti-IudR/BrdU Monoclonal Antibody
For the double-labeling technique designed to simultaneously detect S-phase cells and programmed cell death, sections were first processed for ISEL as described above, rinsed thoroughly in 0.5 M TBS (0.5 M NaCl in 0.05 M T h buffer, pH 7.5) and treated with 4 N HCI for 15 min. the anti-IudRIBrdU MAb 3D9 (3) diluted 1:200 in 0.5 M TBS containing 0.25% Tween 20 for 60 min at RT, rabbit anti-mouse IgG (Dako; Carpenteria, CA) diluted 1:20 in 0.5 M TBS for 30 min, and with mouse allraline phosphatase-anti-alkaline phosphatase antibody (APAAP; Dako) diluted 1:40 in 0.5 M TBS for 30 min. The sections were rinsed thoroughly with 0.5 M TBS after each incubation. Tissues were then immersed in a solution made as follows. Naphthol AS-MX phosphate (20 mg) was dissolved in 2 ml ofN,M-dimethylformamide and this was added to 100 ml 0.1 M Xis buffer, pH 8.2, at 20'C. Next, 0.1 ml of 1.0 M levamisole was added to the solution to inhibit endogenous alkaline phosphatase, followed by 100 mg of Fast Blue BB salt. This mixture was stirred for 2 min and then filtered before the sections were immersed. Color development took 8-10 min. The specimens were then washed in distilled water and mounted with Fluoromount.
Control Experiments for Cell Cycle Studies
These have been previously described in considerable detail (1-3).
Control Experiments for ISEL Technique
Several types of control experiments were initially performed to establish the reproducibility of the ISEL technique. These are described below:
Positive Controls Detection of PCD in PeripheralBloodMononuclear (PBM) Cells. The technique of ISEL has been described by Wijsman et al. (4) in paraffinembedded tissue. To adapt this methodology for plastic-embedded specimens, we first began by using PBM cells. Programmed cell death was induced in these cells by treatment with cycloheximide. The cell pellet was then embedded in plastic with glycol methacrylate as described above for the BM biopsies. A second pellet of untreated PBM cells was also embedded in plastic simultaneously. Sections 2-3 pm thick from each block were then processed for ISEL. The results clearly showed the presence of labeling in a few morphologically apparent apoptotic cells as well as a number of other PBM cells in the cycloheximide-treated group. In the untreated group, only a rare morphologically karyorrhectic cell was labeled. This experiment established our ability to perform ISEL in plastic-embedded tissue. The necessary modifications required for this transition from paraffin to plastic are detailed above.
Detection of PCD in BM Biopsies of Chemotherapy-treated AIUL Patients. Several biopsies from AML patients who were heavily pre-treated or who were undergoing remission induction therapy andwho showed the presence of large numbers of morphologically recognizable karyorrhectic myeloblasts were chosen. The ISEL technique in these individuals dearly showed that every apparently apoptotic cell was also positively stained.
Detection of PCD in N o d BM Biopsies fmm Non-Hodgkin 'I Lymphoma Patients Undergoing Ftatment with a Combination
Cbemotherapy Pmtocol. BM biopsies were also examined from two NHL patients who had no marrow involvement by lymphoma but who were receiving chemotherapy. Once again, large numbers of morphologically apoptotic and many otherwise normal-looking hematopoietic cells were positively stained by the ISEL technique.
Negative Controls. ISEL solution devoid of DNA polymerase was used on control samples as negative controls. These slides were universally negative.
Assessment of the Incidence of Programmed Cell Death in Normal BM Biopsies
Two patients with NHL were studied at the time of diagnosis for cell cycle kinetics using IudRIBrdU. Neither had involvement of the BM by lymphoma. BM biopsies were obtained from both before the start of chemotherapy. These biopsies were interpreted as being morphologically completely normal by at least two pathologists. ISEL was performed on both these biopsies as well.
Interpretation of BM Biopsy Slides
All slides were examined under a light microscope attached to a television screen. At least three different investigators were involved in the interpretation of each slide (AR being one of them every time).
Proliferation Studies. Immunohistochemical detection of IudR-andlor
BrdU-labeled S-phase cells was accomplished with either the anti-IudR/BrdU MAb 3D9 or the anti-BrdU MAb Br-3. The nuclei of cells engaged in DNA synthesis were stained dark brown in single-labeled slides. The labeling index was obtained by counting only the labeled myeloid cells, as previously described (3). Frequently, erythroid islands and occasional megaCary0cytes were also in S-phase, and these were easily recognizable by their unique morphological appearance. These labeled erythroid and megakaryocytic cells and their unlabeled counterparts were excluded from the LI calculations. At least 2000 cells from five different fields were counted.
Programmed Cell Death Studies by ISEL. Coverslips processed for ISEL were mounted on glass slides and examined on the television screen by a group of observers (AR, SM, and AI were always present). The slides were first scanned under low power. ISELpositive cells demonstrated clear, punctate brown staining over their nuclei, often most marked in the perinuclear area. Areas of apoptosis and PCD were identified if these were present in compartmentalized pockets. The following subjective scoring system was used to approximately quantitate the incidence of PCD: Absent: Less than 15% ISELpositive cells Low: 1*-3+ or 15-30% ISELpositive cells Intermediate: 4+-5' or 31-75 % ISELpositive cells High: 6'4 or >75% ISELpositive cells Simultaneous Proliferation and Programmed Cell Death Studies. In these double-labeled slides, the nuclei of S-phase cells were stained blue, the nuclei of ISEL-positive cells were stained brown, and S-phase cells that were also ISELpositive showed the presence of both stains. All three types of cells were clearly identifiable. Once again, the specific points noted in each ISEL slide as described in the section above were carefully looked for and enumerated. Figure 3 shows a macrophage in an AML patient whose nucleus is intact but the cytoplasm is choked with debris from ISEGpositive apoptotic cells. Figure 4 shows an MDS biopsy double labeled for IudRlBrdU and apoptosis. The S-phase cells are stained blue and the cells undergoing programmed cell death are brown. Clearly, some S-phase cells show both brown and blue staining, indicating that these cells were simultaneously synthesizing DNA and undergoing apoptosis.
Results
Zble 1 lists the five AML patients, all of whom had undetectable or low ISEL staining. Often the dying cells appeared in a discrete cluster that was well compartmentalized, and the dying cells appeared to be non-leukemic hematopoietic cells. The labeling index (U) or % S-phase cells ranged from 38-55% (mean * SD 43.8 k 6.6) in these patients. No S-phase cells were double labeled. In contrast, ' Gable 2 describes the five MDS patients, all of whom had at least 30% cells undergoing PCD. The FAB (French-American-British) classification is provided for the patients, as are their LI values (mean LI k SD 33.6 * 9.7). The difference between mean LI values for AML and MDS was statistically significant (p = 0.088, pooled variance t-test). The significant findings in MDS biopsies were: (a) an unusually high incidence of ISEL positive cells; (b) apoptosis of stromal components such as fat cells, endothelial cells and fibroblasts; and (c) apoptosis of large numbers of S-phase cells. Table 3 compares normal biopsies with AML and MDS data with regard to all of these characteristics of proliferation and apoptosis.
The two normal BM biopsies from NHL patients showed only rare apoptotic cells, with a few compartments of intermediate ISEL positivity. No S-phase cells were double labeled and the proliferation rate was not quite as high as that observed in AML or MDS. Stromal cells were only rarely apoptotic.
Discussion
We describe here the development and application of a novel double-labeling technique to simultaneously measure cell birth and cell death rates in BM biopsies of 10 patients with AML and MDS. Because of the biological importance of these findings, it is imperative that we confirm the validity of our ISEL technique. Therefore, we would like to critically analyze the controls used in our study and the reasons why we are convinced that the ISEL technique measures programmed cell death. We proposed the following reasons:
First, are we confusing DNA synthesis in S-phase cells with detection of programmed cell death by ISEL? The obvious answer is no, because double-labeled slides showed that not every S-phase cell was ISELpositive. Furthermore, if we were detecting S-phase cells by ISEL, then the AML biopsies that have the highest U should have shown the maximal staining by ISEL. In fact, AML myeloblasts have the least incidence of programmed cell death.
Second, is it possible that we are measuring DNA repair or unscheduled DNA synthesis by the ISEL technique rather than PCD? The answer to this question is also negative. Consider the following. Almost every cell in the body is engaged in some degree of DNA repair at any given time. However, the segments involved are extremely short (SO-100,000 BP total per cell) and considerably below the sensitivity of detection by the ISEL method (8). Further- Fourth, macrophages were frequently saturated with ISELpositive debris in their cytoplasm but showed no staining of their own nuclei. This is a level of specificity that is hard to question, especially because one can see such cells clearly by light microscopy (Figure 3) . Finally, we have examined some head and neck tumors (data not reported here) in which distinct areas of proliferation, apoptosis, and necrosis were clearly identified. The majority of ISELpositive cells appeared in these geographically restricted areas, although individual apoptotic cells were also identified throughout the sections. This very unique spatial distribution of dying cells, along with the presence of karyorrhectic nuclei in the vicinity, provides further proof that ISEL indeed measures only cells in the various stages of apoptosis.
Our data demonstrate a dramatically high incidence of programmed cell death in the BM biopsies of MDS patients, involving all three lineages of hematopoietic cells (i.e., erythroid, myeloid, and megakaryocytic). In addition, larger numbers of S-phase cells and normal stromal elements in the bone marrow were undergoing apoptotic cell death. Our recent studies have demonstrated the presence of high levels of a known inducer of apoptosis, i.e., tumor necrosis factor-a in the bone marrow microenvironment of MDS patients, which may therefore be responsible for the extensive apoptosis of both hematopoietic and stromal cells in these bone marrows (9). In contrast, the AML patients had a much lower overall incidence of apoptosis, and no S-phase cells were ISEL-positive. These findings appear to be the specific features of these disorders, since apoptosis can occur in any phase of the cell cycle and therefore is an independent cellular process (10).
The ability to measure cell birth and cell death rates simultaneously in situ has significant prognostic and therapeutic implications. For example, since the basis for ineffective hematopoiesis appears to be an extremely high rate of intramedullary cell death, it is logical to propose treatment of MDS patients with agents that suppress apoptosis. The converse would be true for AML patients, in whom the efficacy of a variety of chemoor biotherapeutic agents could be tested by examining the post-treatment biopsies for the induction of apoptosis. Furthermore, the true doubling time of tumors can be calculated accurately by subtracting the ISELpositive cells from the "growth fraction."
In summary, therefore, we report here on a novel double-labeling method that allows simultaneous detection of proliferation and apoptosis in human tumors. Because the technique is applicable to biopsy tissues, it can be used in a variety of malignancies, including both solid and liquid tumors. The data thus obtained are , far more reliable and informative, since one has the luxury of morphological examination in architecturally preserved tumor tissues. When two disorders of the myeloid cells (AML and MDS) were examined, we identified rather distinctive characteristics. The implications of these findings for future biological and clinical studies are obvious.
